Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K, Kinoshita R, Tomonobu N, Gohara Y, Tomida S, Takahashi Y, Senoo S, Taniguchi A, Itano J, Yamamoto KI, Murata H, Suzawa K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Ichimura K, Nishibori M, Miyahara N, Toyooka S, Sakaguchi M. Araki K, et al. Among authors: itano j. J Mol Med (Berl). 2021 Jan;99(1):131-145. doi: 10.1007/s00109-020-02001-x. Epub 2020 Nov 9. J Mol Med (Berl). 2021. PMID: 33169236 Free article.
Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation.
Oda N, Miyahara N, Taniguchi A, Morichika D, Senoo S, Fujii U, Itano J, Gion Y, Kiura K, Kanehiro A, Maeda Y. Oda N, et al. Among authors: itano j. Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L407-L417. doi: 10.1152/ajplung.00386.2018. Epub 2019 Jan 3. Am J Physiol Lung Cell Mol Physiol. 2019. PMID: 30604629 Free article.
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Higo H, Miyahara N, Taniguchi A, Senoo S, Itano J, Watanabe H, Oda N, Kayatani H, Ichikawa H, Shibayama T, Kajimoto K, Tanimoto Y, Kanehiro A, Maeda Y, Kiura K; OKAYAMA respiratory disease study group (ORDSG). Higo H, et al. Among authors: itano j. Respir Investig. 2020 May;58(3):185-189. doi: 10.1016/j.resinv.2019.12.007. Epub 2020 Feb 23. Respir Investig. 2020. PMID: 32102769 Free article.
Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S, Miyahara N, Taniguchi A, Oda N, Itano J, Higo H, Hara N, Watanabe H, Kano H, Suwaki T, Fuchimoto Y, Kajimoto K, Ichikawa H, Kudo K, Shibayama T, Tanimoto Y, Kuyama S, Kanehiro A, Maeda Y, Kiura K; Okayama Respiratory Disease Study Group (ORDSG). Senoo S, et al. Among authors: itano j. PLoS One. 2020 Aug 27;15(8):e0236935. doi: 10.1371/journal.pone.0236935. eCollection 2020. PLoS One. 2020. PMID: 32853277 Free PMC article.
Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis.
Senoo S, Taniguchi A, Itano J, Oda N, Morichika D, Fujii U, Guo L, Sunami R, Kanehiro A, Tokioka F, Yoshimura A, Kiura K, Maeda Y, Miyahara N. Senoo S, et al. Among authors: itano j. Am J Physiol Lung Cell Mol Physiol. 2021 Nov 1;321(5):L925-L940. doi: 10.1152/ajplung.00582.2020. Epub 2021 Sep 15. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 34524907 Free article.
50 results